Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Jerome Hanna"'
Autor:
Namuwulya, Prossy, Ashraf, Shirin, Niebel, Marc, Ssekagiri, Alfred, Tushabe, Phionah, Kakooza, Proscovia, Tong, Lily, Bukenya, Henry, Jerome, Hanna, Davis, Chris, Birungi, Molly, Turyahabwe, Irene, Mugaga, Arnold, Eliku, James Peter, Francis, Aine, Nakabazzi, Lucy, Nsubuga, Fred, Katushabe, Edson, Kisakye, Annet, Ampeire, Immaculate, Nanteza, Ann, Kaleebu, Pontiano, Bakamutumaho, Barnabas, Nsamba, Peninah, Kazibwe, Anne, da Silva Filipe, Ana, Tweyongyere, Robert, Bwogi, Josephine, Thomson, Emma C.
Publikováno v:
In Journal of Infection May 2024 88(5)
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Annette Wundes, Sibyl Wray, Ralf Gold, Barry A. Singer, Elzbieta Jasinska, Tjalf Ziemssen, Jerome de Seze, Pavle Repovic, Hailu Chen, Jerome Hanna, Jordan Messer, Catherine Miller, Robert T. Naismith
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background: Diroximel fumarate (DRF) is a novel oral fumarate approved for relapsing forms of multiple sclerosis (MS). DRF demonstrated significantly improved gastrointestinal (GI) tolerability versus dimethyl fumarate (DMF) with fewer days of Indivi
Externí odkaz:
https://doaj.org/article/7dcf8de81cf441938990675a654ee297
Autor:
Patrick Vermersch, Matthew Scaramozza, Seth Levin, Raed Alroughani, Kumaran Deiva, Carlo Pozzilli, Jennifer Lyons, Oksana Mokliatchouk, Joe Pultz, Fatou N’Dure, Shifang Liu, Runda Badwan, Filipe Branco, Valencia Hood-Humphrey, Nathalie Franchimont, Jerome Hanna, Amir-Hadi Maghzi
Publikováno v:
JAMA network open. 5(9)
ImportanceWith few approved multiple sclerosis therapies in the pediatric population, there is a need for further approved treatment options. Limited data exist for dimethyl fumarate (DMF) treatment in pediatric-onset multiple sclerosis (POMS).Object
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a9da75e90d49bf0dd6287d866d95a5c
https://pubmed.ncbi.nlm.nih.gov/36169961
https://pubmed.ncbi.nlm.nih.gov/36169961
Autor:
Robert T. Naismith, Elzbieta Jasinska, Hailu Chen, Jennifer L. Lyons, Maria Lopez-Bresnahan, Annette Wundes, Tjalf Ziemssen, David Rezendes, Jerry S. Wolinsky, Anthony Lembo, Richard Leigh-Pemberton, Krzysztof Selmaj, Catherine Miller, Ilda Bidollari, Jerome Hanna, Mark S. Freedman
Publikováno v:
CNS Drugs
Background Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF). DRF 462 mg and DM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca8913e2f749d7400243f5d2ebf08015
http://europepmc.org/articles/PMC7018784
http://europepmc.org/articles/PMC7018784
Autor:
Lili Yang, Hailu Chen, Douglas L. Arnold, Catherine Miller, David Rezendes, Boris Kandinov, Christopher LaGanke, Jerry S. Wolinsky, Mark S. Freedman, Maria Lopez-Bresnahan, Narinder Nangia, Dragana Obradovic, Jerome Hanna, Tjalf Ziemssen, Annette Wundes, Robert T. Naismith, Richard Leigh-Pemberton, Ilda Bidollari, Mark Gudesblatt, Shifang Liu
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: Diroximel fumarate (DRF) is a novel oral fumarate for patients with relapsing–remitting multiple sclerosis (RRMS). DRF and the approved drug dimethyl fumarate yield bioequivalent exposure to the active metabolite monomethyl fumarate; th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e640589855d107759e6c8b6cdb11ba81
http://europepmc.org/articles/PMC7604551
http://europepmc.org/articles/PMC7604551
Autor:
Catherine Miller, Natasha Penner, Richard Leigh-Pemberton, Kristopher Perkin, Angela Wehr, Mark Tawa, Michael J. Palte, Jerome Hanna
Publikováno v:
Advances in Therapy
Introduction Diroximel fumarate (DRF) is a novel oral fumarate in development for patients with relapsing forms of multiple sclerosis (MS). Clinical findings from the DRF development program suggest that rates of gastrointestinal (GI) treatment-emerg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64eaa7c4a7490140a256f790dae1d74f
http://europepmc.org/articles/PMC6822793
http://europepmc.org/articles/PMC6822793
Autor:
Amir-Hadi Maghzi, Seth Levin, Raed Alroughani, Kumaran Deiva, Carlo Pozzilli, Jennifer Lyons, Oksana Mokliatchouk, Joe Pultz, Shifang Liu, Runda Badwan, Filipe Branco, Nathalie Franchimont, Jerome Hanna, Matthew Scaramozza, Patrick Vermersch, Fatou N’Dure
Publikováno v:
Revue Neurologique. 178:S116
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7dbe33a0d7f48fa1cf57aa445db0200
https://doi.org/10.1016/j.neurol.2022.02.391
https://doi.org/10.1016/j.neurol.2022.02.391
Autor:
Robert J. Fox, Ralf Gold, J. Theodore Phillips, Shifang Liu, L Kappos, Christian von Hehn, Catherine Miller, Karen Spach, Derrick Robertson, Jordana Campbell, Devangi Mehta, André Palma da Cunha Matta, Eris Bame, Douglas L. Arnold, Lili Yang, A Bar-Or, Jerome Hanna
Publikováno v:
Neurology
ObjectiveTo assess functional changes in lymphocyte repertoire and subsequent clinical implications during delayed-release dimethyl fumarate (DMF) treatment in patients with multiple sclerosis.MethodsUsing peripheral blood from several clinical trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09971221f667968a4f6357d4df96428a
https://pubmed.ncbi.nlm.nih.gov/30918089
https://pubmed.ncbi.nlm.nih.gov/30918089
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.